The global pruritus therapeutics market is anticipated to reach over USD 17,275.12 Million by 2026, according to a new research published by Polaris Market Research, Pruritus, also known as itch disorder can be triggered by several ailments ranging from dermatological disorders such as mycoses, atopic dermatitis, chickenpox, and contact dermatitis, Pruritus is interrelated with the dermatologic and systemic causes. A typical itching generally forms the diagnosis of a key dermatologic syndrome. Several skin diseases that are related to pruritus include renal pruritus, hematologic pruritus, cholestatic pruritus, idiopathic generalized pruritus, pruritus related to malignancy and endocrine pruritus. Renal pruritus can befall in people with chronic renal failure. Increased levels of ions such as calcium, phosphate, and magnesium are found in the skin of pruritic patients. Severe pruritus leads to scratching that causes secondary skin problems such as eczematization, dryness, infection, excoriation, Contact allergy, and lichenification.
The rising incidence of dermatological disorder influencing the occurrence of pruritus and subsequently, the rising demand for proper diagnostics as well as therapeutics to treat the such medical condition is anticipated to bolster the market growth. The rise in inorganic development strategies is recognized as one of the key factor boosting the growth of the pruritus therapeutic market. In addition, the key players of the pruritus therapeutic market are progressively adapting the growth strategies such as partnerships, regional acquirements, and mergers and acquisitions. Such growth strategies are anticipated to result in technological advancement owing to enhancement in the product portfolio and mutual collaboration in R&D further boosting the market growth.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:
The global pruritus therapeutics market is segmented on the basis of product, disease type, and geography. On the basis of product, the global pruritus therapeutics market is segmented into Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, and Others. In 2017, the corticosteroids are expected to dominate the market by product segment as corticosteroids are widely used as the first line of treatment. On the basis of disease type, the global pruritus therapeutics market is segmented into Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, and Others. In 2017, Allergic contact dermatitis is estimated to dominate the market segment. It is the 3rd most general cause for patients seeking consultation with a dermatology specialist. Allergic contact dermatitis is commonly observed in women.
On the basis of region, the global pruritus therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was estimated to dominate the global pruritus therapeutics market. The dominance is majorly due to The presence of favorable government initiatives and the introduction of new products. Moreover, rising incidence of target disorders and the existence of pruritus inducing climatic disorders in this region are anticipated to boost the market growth during the forecast period. However, Asia Pacific is anticipated to dominate pruritus therapeutics market. Growing incidence of atopic dermatitis and urticarial and presence of unmet healthcare organization needs are the factors attributed to the growth of the market in Asia Pacific.
Some major key players in global Pruritus Therapeutics Market include pruritus therapeutics market includes Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical Industries Ltd. among others.